These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19672900)

  • 21. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

  • 22. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
    Gabriel SE
    Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
    [No Abstract]   [Full Text] [Related]  

  • 25. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 26. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis.
    Moreland LW
    Isr Med Assoc J; 2001 Sep; 3(9):686-90. PubMed ID: 11574988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163
    [No Abstract]   [Full Text] [Related]  

  • 28. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
    Ledingham J; Deighton C;
    Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
    [No Abstract]   [Full Text] [Related]  

  • 29. [Danish data document therapeutic effect differences of tumor necrosis factor inhibitors in patient with rheumatoid arthritis].
    Hetland ML
    Ugeskr Laeger; 2010 Jun; 172(26):2003; author reply 2003-4. PubMed ID: 20681045
    [No Abstract]   [Full Text] [Related]  

  • 30. Guidance for practitioners on the assessment, administration and monitoring of biologic therapies for inflammatory arthritis.
    Oliver S
    Musculoskeletal Care; 2003 Sep; 1(2):135-40. PubMed ID: 20217674
    [No Abstract]   [Full Text] [Related]  

  • 31. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 32. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
    Ostergaard M; Unkerskov J; Linde L; Krogh NS; Ravn T; Ringsdal VS; Petri A; Andersen LS; Tarp U; Hansen A; Hjardem E; Hetland ML
    Scand J Rheumatol; 2007; 36(2):151-4. PubMed ID: 17476624
    [No Abstract]   [Full Text] [Related]  

  • 33. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?
    O'Dell JR
    N Engl J Med; 1999 Jan; 340(4):310-2. PubMed ID: 9920958
    [No Abstract]   [Full Text] [Related]  

  • 35. The 'alphabet' of rheumatoid arthritis treatment.
    Capriotti T
    Medsurg Nurs; 2004 Dec; 13(6):420-8. PubMed ID: 15714747
    [No Abstract]   [Full Text] [Related]  

  • 36. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trials reveal promising options for treating juvenile rheumatoid arthritis.
    Hampton T
    JAMA; 2008 Jan; 299(1):27-8. PubMed ID: 18167400
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
    Cairns AP; Taggart AJ
    Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TNF blocker drugs used to fight inflammation go head-to-head. Adalimumab had highest treatment response and remission rates, etanercept has longest drug survival rates; infliximab placed third.
    Duke Med Health News; 2010 Mar; 16(3):3. PubMed ID: 20461880
    [No Abstract]   [Full Text] [Related]  

  • 40. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.